39 results
8-K
EX-99.1
BHVN
Biohaven Ltd.
9 May 24
Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments
4:14pm
our Molecular Degrader of Extracellular Protein (MoDE™) technology. We were pleased to report preliminary safety and target engagement data showing
8-K
EX-99.1
BHVN
Biohaven Ltd.
29 Feb 24
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
4:16pm
of GABAA receptor activation and lack of adverse impacts on neurobehavior in preclinical testing.
Demonstrated CNS target engagement: In December … engagement in the brain as shown by dose-dependent effects on EEG spectral power across all frequency bands. While changes in spectral power were
8-K
EX-99.1
7xpczilv q6dc4i
8 Jan 24
Regulation FD Disclosure
7:30am
8-K
EX-99.1
jnteg8f weco
14 Nov 23
Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments
4:26pm
8-K
EX-1.1
7m08k3l1c5h
2 Oct 23
Other Events
9:41pm
8-K
EX-99.1
gpu4fg41 6a22ggvwnfo
27 Sep 23
Regulation FD Disclosure
6:58am
8-K
EX-99.1
dihaozvxtm
31 Jul 23
Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments
4:29pm
8-K
EX-99.1
a40he0es
28 Jul 23
Biohaven Provides Preliminary EEG Data Update for Kv7 Platform, Regulatory Update on Troriluzole and Other Corporate Updates
4:35pm
8-K
EX-99.1
9r9bnl4 1r7su
12 May 23
Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments
4:47pm
10-Q
sg0hfh a8
9 Nov 22
Quarterly report
4:19pm
424B4
pk034sus
24 Oct 22
Prospectus supplement with pricing info
9:38am
S-1/A
ohfp7nv0 pb60r7
20 Oct 22
IPO registration (amended)
10:00am
S-1
bu5 56a9sx0x02bpljm
18 Oct 22
IPO registration
4:03pm
DRS
gi9 f21s9zz
11 Oct 22
Draft registration statement
12:00am